Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
A recent report that 93 per cent of invasive cervical cancers worldwide contain human papillomavirus (HPV) may be an underestimate, due to sample inadequacy or integration events affecting the HPV L1 gene, which is the target of the polymerase chain reaction (PCR)-based test which was used. The formerly HPV-negative cases from this study have therefore been reanalyzed for HPV serum antibodies and HPV DNA. Serology for HPV 16 VLPs, E6, and E7 antibodies was performed on 49 of the 66 cases which were HPV-negative and a sample of 48 of the 866 cases which were HPV-positive in the original study.
Moreover, 55 of the 66 formerly HPV-negative biopsies were also reanalyzed by a sandwich procedure in which the outer sections in a series of sections are used for histological review, while the inner sections are assayed by three different HPV PCR assays targeting different open reading frames (ORFs). No significant difference was found in serology for HPV 16 proteins between the cases that were originally HPV PCR-negative and -positive. Type-specific E7 PCR for 14 high-risk HPV types detected HPV DNA in 38 (69 per cent) of the 55 originally HPV-negative and amplifiable specimens. The HPV types detected were 16, 18, 31, 33, 39, 45, 52, and 58. Two (4 per cent) additional cases were only HPV DNA-positive by E1 and/or L1 consensus PCR. Histological analysis of the 55 specimens revealed that 21 were qualitatively inadequate. Only two of the 34 adequate samples were HPV-negative on all PCR tests, as against 13 of the 21 that were inadequate ( p< 0.001).
Combining the data from this and the previous study and excluding inadequate specimens, the worldwide HPV prevalence in cervical carcinomas is 99.7 per cent. The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer. The extreme rarity of HPV-negative cancers reinforces the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia.In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020.Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market.
The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient).
According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax. 17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure.The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection.National Key R&D Program of China.
AFLP: a new technique for DNA fingerprinting.
A novel DNA fingerprinting technique called AFLP is described. The AFLP technique is based on the selective PCR amplification of restriction fragments from a total digest of genomic DNA. The technique involves three steps: (i) restriction of the DNA and ligation of oligonucleotide adapters, (ii) selective amplification of sets of restriction fragments, and (iii) gel analysis of the amplified fragments.
PCR amplification of restriction fragments is achieved by using the adapter and restriction site sequence as target sites for primer annealing. The selective amplification is achieved by the use of primers that extend into the restriction fragments, amplifying only those fragments in which the primer extensions match the nucleotides flanking the restriction sites. Using this method, sets of restriction fragments may be visualized by PCR without knowledge of nucleotide sequence. The method allows the specific co-amplification of high numbers of restriction fragments. The number of fragments that can be analyzed simultaneously, however, is dependent on the resolution of the detection system. Typically 50-100 restriction fragments are amplified and detected on denaturing polyacrylamide gels. The AFLP technique provides a novel and very powerful DNA fingerprinting technique for DNAs of any origin or complexity.
Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.
Accurate normalization is an absolute prerequisite for correct measurement of gene expression. For quantitative real-time reverse transcription-PCR (RT-PCR), the most commonly used normalization strategy involves standardization to a single constitutively expressed control gene. However, in recent years, it has become clear that no single gene is constitutively expressed in all cell types and under all experimental conditions, implying that the expression stability of the intended control gene has to be verified before each experiment.
We outline a novel, innovative, and robust strategy to identify stably expressed genes among a set of candidate normalization genes. The strategy is rooted in a mathematical model of gene expression that enables estimation not only of the overall variation of the candidate normalization genes but also of the variation between sample subgroups of the sample set.
Notably, the strategy provides a direct measure for the estimated expression variation, enabling the user to evaluate the systematic error introduced when using the gene. In a side-by-side comparison with a previously published strategy, our model-based approach performed in a more robust manner and showed less sensitivity toward coregulation of the candidate normalization genes. We used the model-based strategy to identify genes suited to normalize quantitative RT-PCR data from colon cancer and bladder cancer. These genes are UBC, GAPD, and TPT1 for the colon and HSPCB, TEGT, and ATP5B for the bladder. The presented strategy can be applied to evaluate the suitability of any normalization gene candidate in any kind of experimental design and should allow more reliable normalization of RT-PCR data.
Hamster Uterus cDNA |
|||
| AD-411 | Zyagen | 30 reactions | EUR 243 |
MiniPig Uterus cDNA |
|||
| ND-411 | Zyagen | 30 reactions | EUR 358 |
Guinea Pig Uterus cDNA |
|||
| GD-411 | Zyagen | 30 reactions | EUR 243 |
Cat Uterus Total RNA* |
|||
| FR-411 | Zyagen | 0.05mg | EUR 195 |
Cat Uterus Genomic DNA |
|||
| FG-411 | Zyagen | 0.1mg | EUR 210 |
Cat Uterus Total Protein |
|||
| FT-411 | Zyagen | 1mg | EUR 176 |
cDNA - Human Tumor Tissue: Uterus |
|||
| C1235274 | Biochain | 40 reactions | EUR 636 |
Rat Uterus, non-pregnant cDNA |
|||
| RD-411 | Zyagen | 30 reactions | EUR 243 |
Mouse CD1 Uterus, non-pregnant cDNA |
|||
| MD-411 | Zyagen | 30 reactions | EUR 243 |
Mouse BLC Uterus, non-pregnant cDNA |
|||
| MD-411-BLC | Zyagen | 30 reactions | EUR 280 |
Mouse C57 Uterus, non-pregnant cDNA |
|||
| MD-411-C57 | Zyagen | 30 reactions | EUR 280 |
cDNA - Human Adult Normal Tissue: Uterus |
|||
| C1234274 | Biochain | 40 reactions | EUR 424 |
cDNA - Monkey (Rhesus) Normal Tissue: Uterus |
|||
| C1534274 | Biochain | 40 reactions | EUR 723 |
cDNA - Monkey (Cynomolgus) Normal Tissue: Uterus |
|||
| C1534274-Cy | Biochain | 40 reactions | EUR 723 |
cDNA - Human Adult Normal Tissue: Uterus: Cervix |
|||
| C1234275 | Biochain | 40 reactions | EUR 424 |
cDNA - Human Adult Normal Tissue: Uterus: Corpus |
|||
| C1234276-10 | Biochain | 10 reactions | EUR 237 |
cDNA - Human Adult Normal Tissue: Uterus: Fundus |
|||
| C1234278-10 | Biochain | 10 reactions | EUR 237 |
cDNA - Monkey (Rhesus) Normal Tissue: Uterus: Cervix |
|||
| C1534275 | Biochain | 40 reactions | EUR 723 |
cDNA - Monkey (Rhesus) Normal Tissue: Uterus: Corpus |
|||
| C1534276 | Biochain | 40 reactions | EUR 723 |
cDNA - Monkey (Rhesus) Normal Tissue: Uterus: Fundus |
|||
| C1534278 | Biochain | 40 reactions | EUR 723 |
Rat Uterus, non-pregnant cDNA-Random Primer |
|||
| RD-411-RH | Zyagen | 30 reactions | EUR 243 |
cDNA - Monkey (Cynomolgus) Normal Tissue: Uterus: Cervix |
|||
| C1534275-Cy | Biochain | 40 reactions | EUR 723 |
Rat WS Uterus, non-pregnant cDNA-Oligo-dT |
|||
| RD-411-WS | Zyagen | 30 reactions | EUR 243 |
Mouse C57 Uterus, non-pregnant cDNA-Random Primer |
|||
| MD-411-C57-RH | Zyagen | 30 reactions | EUR 280 |
Mouse CD1 Uterus, non-pregnant cDNA-Random Primer |
|||
| MD-411-HR | Zyagen | 30 reactions | EUR 243 |
Tissue cDNA, First Strand, Human Tumor, Uterus, BioGenomics |
|||
| MBS651979-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Human Tumor, Uterus, BioGenomics |
|||
| MBS651979-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, BioGenomics |
|||
| MBS651999-40Tests | MyBiosource | 40Tests | EUR 680 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, BioGenomics |
|||
| MBS651999-5x40Tests | MyBiosource | 5x40Tests | EUR 2835 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Corpus, BioGenomics |
|||
| MBS652435-10Tests | MyBiosource | 10Tests | EUR 540 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Corpus, BioGenomics |
|||
| MBS652435-5x10Tests | MyBiosource | 5x10Tests | EUR 2215 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Fundus, BioGenomics |
|||
| MBS652490-10Tests | MyBiosource | 10Tests | EUR 540 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Fundus, BioGenomics |
|||
| MBS652490-5x10Tests | MyBiosource | 5x10Tests | EUR 2215 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Cervix, BioGenomics |
|||
| MBS651890-40Tests | MyBiosource | 40Tests | EUR 680 |
Tissue cDNA, First Strand, Human Adult Normal, Uterus, Cervix, BioGenomics |
|||
| MBS651890-5x40Tests | MyBiosource | 5x40Tests | EUR 2835 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, BioGenomics |
|||
| MBS652015-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, BioGenomics |
|||
| MBS652015-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Monkey (Cynomolgus) Adult Normal, Uterus, BioGenomics |
|||
| MBS652498-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Cynomolgus) Adult Normal, Uterus, BioGenomics |
|||
| MBS652498-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Cervix, BioGenomics |
|||
| MBS652482-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Cervix, BioGenomics |
|||
| MBS652482-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Fundus, BioGenomics |
|||
| MBS652111-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Fundus, BioGenomics |
|||
| MBS652111-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Corpus, BioGenomics |
|||
| MBS652277-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Rhesus) Adult Normal, Uterus, Corpus, BioGenomics |
|||
| MBS652277-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Tissue cDNA, First Strand, Monkey (Cynomolgus) Adult Normal, Uterus, Cervis, BioGenomics |
|||
| MBS651910-40Tests | MyBiosource | 40Tests | EUR 850 |
Tissue cDNA, First Strand, Monkey (Cynomolgus) Adult Normal, Uterus, Cervis, BioGenomics |
|||
| MBS651910-5x40Tests | MyBiosource | 5x40Tests | EUR 3600 |
Uterus, Rabbit |
|||
| MBS639336-25Each | MyBiosource | 25Each | EUR 395 |
Uterus, Rabbit |
|||
| MBS639336-5x25Each | MyBiosource | 5x25Each | EUR 1550 |
Uterus, Bovine |
|||
| MBS639365-5Each | MyBiosource | 5Each | EUR 395 |
Uterus, Bovine |
|||
| MBS639365-5x5Each | MyBiosource | 5x5Each | EUR 1550 |
Uterus Lysate |
|||
| MBS151639-01mg | MyBiosource | 0.1mg | EUR 200 |
Uterus Lysate |
|||
| MBS151639-5x01mg | MyBiosource | 5x0.1mg | EUR 880 |
Dog Uterus RNA* |
|||
| DR-411 | Zyagen | 0.05mg | EUR 195 |
Total RNA - Human Adult Normal Tissue: Uterus: Cervix of uterus |
|||
| R1234275-50 | Biochain | 50 ug | EUR 221 |
Total RNA - Human Adult Normal Tissue: Uterus: Corpus of Uterus |
|||
| R1234276-10 | Biochain | 10 ug | EUR 229 |
BOVINE, UTERUS, FRESH |
|||
| 8600861 | Lampire Biologicals Laboratories | 1EA | EUR 67.09 |
Uterus Tissue block |
|||
| 29 | BioCoreUSA | 1 unit | EUR 535 |
Fetal Uterus Lysate |
|||
| XBL-10431 | ProSci | 0.1 mg | EUR 632.4 |
|
Description: Fetal human uterus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The fetal human uterus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the uterus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The uterus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
|||
Uterus Tumor Lysate |
|||
| MBS151717-01mg | MyBiosource | 0.1mg | EUR 260 |
Uterus Tumor Lysate |
|||
| MBS151717-5x01mg | MyBiosource | 5x0.1mg | EUR 1140 |
PORCINE, UTERUS, FRESH |
|||
| 8604961 | Lampire Biologicals Laboratories | 1EA | EUR 65.63 |
BOVINE, UTERUS, FROZEN |
|||
| 8620861 | Lampire Biologicals Laboratories | 1EA | EUR 67.09 |
PORCINE, UTERUS, FROZEN |
|||
| 8624961 | Lampire Biologicals Laboratories | 1EA | EUR 65.63 |
Rat Uterus Fibroblasts |
|||
| ABC-TC4237 | AcceGen | 1 vial | Ask for price |
|
Description: Rat uterus fibroblasts, 6-week Wistar rat |
|||
Uterus Membrane Lysate |
|||
| XBL-11023 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Human uterus tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human uterus tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated uterus tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated uterus tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
OORA00351-10U - UTERUS |
|||
| OORA00351-10U | Aviva Systems Biology | 1Each | EUR 105 |
OORA00351-1EA - UTERUS |
|||
| OORA00351-1EA | Aviva Systems Biology | 1Each | EUR 99 |
OORA00493-10U - UTERUS |
|||
| OORA00493-10U | Aviva Systems Biology | 1Each | EUR 55 |
OORA00493-1EA - UTERUS |
|||
| OORA00493-1EA | Aviva Systems Biology | 1Each | EUR 59 |
Tissue, Total RNA, Human Adult Normal, Uterus, Corpus of Uterus, BioGenomics |
|||
| MBS638682-001mg | MyBiosource | 0.01mg | EUR 485 |
Tissue, Total RNA, Human Adult Normal, Uterus, Corpus of Uterus, BioGenomics |
|||
| MBS638682-5x001mg | MyBiosource | 5x0.01mg | EUR 1960 |
Tissue, Total RNA, Human Adult Normal, Uterus, Cervix of uterus, BioGenomics |
|||
| MBS638538-005mg | MyBiosource | 0.05mg | EUR 495 |
Tissue, Total RNA, Human Adult Normal, Uterus, Cervix of uterus, BioGenomics |
|||
| MBS638538-5x005mg | MyBiosource | 5x0.05mg | EUR 1995 |
Pig Uterus Total RNA |
|||
| PR-411 | Zyagen | 0.1mg | EUR 235 |
Dog Uterus Genomic DNA |
|||
| DG-411 | Zyagen | 0.1mg | EUR 210 |
Pig Uterus Genomic DNA |
|||
| PG-411 | Zyagen | 0.1mg | EUR 177 |
Total RNA - Lupus: Uterus |
|||
| R1236274Lup-50 | Biochain | 50 ug | EUR 460 |
Rat Uterus Genomic DNA |
|||
| RG-411 | Zyagen | 0.1mg | EUR 177 |
Sheep Uterus Total RNA |
|||
| SR-411 | Zyagen | 0.1mg | EUR 160 |
Bovine Uterus Total RNA |
|||
| BR-411 | Zyagen | 0.1mg | EUR 160 |
Rabbit Uterus Total RNA |
|||
| TR-411 | Zyagen | 0.1mg | EUR 160 |
Total RNA - Human Adult Normal Tissue 5 Donor Pool: Uterus: Cervix of uterus |
|||
| R1234275-P | Biochain | 50 ug | EUR 443 |
Dog Uterus Total Protein |
|||
| DT-411 | Zyagen | 1mg | EUR 176 |
Hamster Uterus Total RNA* |
|||
| AR-411 | Zyagen | 0.05mg | EUR 160 |
Human Uterus Genomic DNA |
|||
| HG-411 | Zyagen | 0.05mg | EUR 210 |
Pig Uterus Total Protein |
|||
| PT-411 | Zyagen | 1mg | EUR 153 |
MiniPig Uterus Total RNA |
|||
| NR-411 | Zyagen | 0.1mg | EUR 231 |
Mouse Uterus Genomic DNA |
|||
| MG-411 | Zyagen | 0.1mg | EUR 177 |
Sheep Uterus Genomic DNA |
|||
| SG-411 | Zyagen | 0.1mg | EUR 177 |
Bovine Uterus Genomic DNA |
|||
| BG-411 | Zyagen | 0.1mg | EUR 177 |
Human Uterus Tumor lysate |
|||
| HTL-1384 | Alpha Diagnostics | 1 mg | EUR 927.6 |
Equine Uterus Genomic DNA |
|||
| GE-411 | Zyagen | 0.1mg | EUR 210 |
OORA00552-1U - Rat UTERUS |
|||
| OORA00552-1U | Aviva Systems Biology | 1Each | EUR 60 |
Rabbit Uterus Genomic DNA |
|||
| TG-411 | Zyagen | 0.1mg | EUR 177 |
Uterus tumor tissue array |
|||
| UT802a | TissueArray | each | EUR 306 |
|
Description: Uterus tumor tissue array, including stromal and leiomyo sarcoma, endometrioid adenocarcinoma, chorionepithelioma, hydatidiform mole, clear cell carcinoma, carcinsarcoma, sarcomatoid carcinoma, with pathology grade, TNM/Stage (AJCC 8th edition), 80 cases/80 cores (cores size 1.5mm), replacing UT802 |
|||
Uterus Tissue Slide (Benign) |
|||
| 11-402-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Benign) |
|||
| 11-402-4um | ProSci | 4 um | EUR 216.6 |
Uterus Tissue Slide (Normal) |
|||
| 11-401-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Normal) |
|||
| 11-401-4um | ProSci | 4 um | EUR 216.6 |
Hamster Uterus Genomic DNA |
|||
| GA-411 | Zyagen | 0.1mg | EUR 177 |
Human Uterus Tissue Lysate |
|||
| IHUUTETL100UG | Innovative research | each | EUR 245 |
|
Description: Human Uterus Tissue Lysate |
|||
OORA00552-1EA - Rat UTERUS |
|||
| OORA00552-1EA | Aviva Systems Biology | 1Each | EUR 59 |
Pig Uterus Frozen Sections |
|||
| PF-411 | Zyagen | 10 slides | EUR 261 |
Chicken Uterus Genomic DNA |
|||
| GC-411 | Zyagen | 0.1mg | EUR 177 |
Sheep Uterus Total Protein |
|||
| ST-411 | Zyagen | 1mg | EUR 153 |
Human Uterus Tissue Lysate |
|||
| MBS8420151-01mg | MyBiosource | 0.1mg | EUR 385 |
Human Uterus Tissue Lysate |
|||
| MBS8420151-5x01mg | MyBiosource | 5x0.1mg | EUR 1540 |
Uterus Tissue Slide (Benign) |
|||
| MBS154229-10um | MyBiosource | 10um | EUR 210 |
Uterus Tissue Slide (Benign) |
|||
| MBS154229-4um | MyBiosource | 4um | EUR 195 |
Uterus Tissue Slide (Benign) |
|||
| MBS154229-5x10um | MyBiosource | 5x10um | EUR 920 |
Uterus Tissue Slide (Normal) |
|||
| MBS154314-10um | MyBiosource | 10um | EUR 210 |
Uterus Tissue Slide (Normal) |
|||
| MBS154314-4um | MyBiosource | 4um | EUR 195 |
Uterus Tissue Slide (Normal) |
|||
| MBS154314-5x10um | MyBiosource | 5x10um | EUR 920 |
Bovine Uterus Total Protein |
|||
| BT-411 | Zyagen | 1mg | EUR 153 |
Rabbit Uterus Total Protein |
|||
| TT-411 | Zyagen | 1mg | EUR 153 |
57153-2 BV UTERUS 5 EA* |
|||
| 57153-2 | Pel-Freez | 5 EA | EUR 300 |
Uterus Tissue Slide (Abnormal) |
|||
| 11-419-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Abnormal) |
|||
| 11-419-4um | ProSci | 4 um | EUR 216.6 |
Chicken Uterus Total Protein |
|||
| CT-411 | Zyagen | 1mg | EUR 140 |
Hamster Uterus Total Protein |
|||
| AT-411 | Zyagen | 1mg | EUR 153 |
Uterus Membrane Tumor Lysate |
|||
| XBL-11031 | ProSci | 0.1 mg | EUR 752.1 |
|
Description: Human uterus tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human uterus tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated uterus tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated uterus tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
OORA00523-1U - Rabbit UTERUS |
|||
| OORA00523-1U | Aviva Systems Biology | 1Each | EUR 255 |
MiniPig Uterus Total Protein |
|||
| NT-411 | Zyagen | 1mg | EUR 176 |
Pig Uterus Paraffin Sections |
|||
| PP-411 | Zyagen | 10 slides | EUR 240 |
Sheep Uterus Frozen Sections |
|||
| SF-411 | Zyagen | 10 slides | EUR 261 |
Uterus Tissue Slide (Abnormal) |
|||
| MBS154337-10um | MyBiosource | 10um | EUR 210 |
Uterus Tissue Slide (Abnormal) |
|||
| MBS154337-4um | MyBiosource | 4um | EUR 195 |
Uterus Tissue Slide (Abnormal) |
|||
| MBS154337-5x10um | MyBiosource | 5x10um | EUR 920 |
Equine Uterus Frozen Sections |
|||
| EF-411 | Zyagen | 10 slides | EUR 261 |
Bovine Uterus Frozen Sections |
|||
| BF-411 | Zyagen | 10 slides | EUR 261 |
OORA00523-1EA - Rabbit UTERUS |
|||
| OORA00523-1EA | Aviva Systems Biology | 1Each | EUR 239 |
Rabbit Uterus Frozen Sections |
|||
| TF-411 | Zyagen | 10 slides | EUR 240 |
Uterus Tissue Slide (Adenomyoma) |
|||
| 11-432-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Adenomyoma) |
|||
| 11-432-4um | ProSci | 4 um | EUR 216.6 |
Hamster Uterus Frozen Sections |
|||
| AF-411 | Zyagen | 10 slides | EUR 240 |
Human Uterus Paraffin Sections |
|||
| HP-411 | Zyagen | 10 slides | EUR 319 |
OORA00470-10U - Hamster UTERUS |
|||
| OORA00470-10U | Aviva Systems Biology | 1Each | EUR 75 |
OORA00470-1EA - Hamster UTERUS |
|||
| OORA00470-1EA | Aviva Systems Biology | 1Each | EUR 69 |
MiniPig Uterus Frozen Sections |
|||
| NF-411 | Zyagen | 10 slides | EUR 307 |
Sheep Uterus Paraffin Sections |
|||
| SP-411 | Zyagen | 10 slides | EUR 240 |
Uterus Tissue Slide (Adenomyoma) |
|||
| MBS154292-10um | MyBiosource | 10um | EUR 210 |
Uterus Tissue Slide (Adenomyoma) |
|||
| MBS154292-4um | MyBiosource | 4um | EUR 195 |
Uterus Tissue Slide (Adenomyoma) |
|||
| MBS154292-5x10um | MyBiosource | 5x10um | EUR 920 |
Bovine Uterus Paraffin Sections |
|||
| BP-411 | Zyagen | 10 slides | EUR 240 |
Uterus-Corpus Membrane Lysate |
|||
| XBL-11037 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Human uterus-corpus tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human uterus-corpus tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated uterus-corpus tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated uterus-corpus tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
Uterus-Fundus Membrane Lysate |
|||
| XBL-11040 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Human uterus-fundus tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human uterus-fundus tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated uterus-fundus tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated uterus-fundus tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
Equine Uterus Paraffin Sections |
|||
| EP-411 | Zyagen | 10 slides | EUR 240 |
OCPB00133-100UG - Uterus Lysate |
|||
| OCPB00133-100UG | Aviva Systems Biology | 0.1mg | EUR 139 |
Rat Uterus-E12 Total RNA |
|||
| RR-411-12 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E13 Total RNA |
|||
| RR-411-13 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E14 Total RNA |
|||
| RR-411-14 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E15 Total RNA |
|||
| RR-411-15 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E16 Total RNA |
|||
| RR-411-16 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E17 Total RNA |
|||
| RR-411-17 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E18 Total RNA |
|||
| RR-411-18 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E19 Total RNA |
|||
| RR-411-19 | Zyagen | 0.05mg | EUR 160 |
Rat Uterus-E20 Total RNA |
|||
| RR-411-20 | Zyagen | 0.05mg | EUR 160 |
Hamster Uterus Paraffin Sections |
|||
| AP-411 | Zyagen | 10 slides | EUR 228 |
MiniPig Uterus Paraffin Sections |
|||
| NP-411 | Zyagen | 10 slides | EUR 307 |
Guinea Pig Uterus Total RNA |
|||
| GR-411 | Zyagen | 0.1mg | EUR 160 |
Mini Pig Uterus Genomic DNA |
|||
| GN-411 | Zyagen | 0.1mg | EUR 210 |
Mouse C57 Uterus Genomic DNA |
|||
| MG-411-C57 | Zyagen | 0.05mg | EUR 210 |
Uterus Tissue Slide (Adenocarcinoma) |
|||
| 11-404-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Adenocarcinoma) |
|||
| 11-404-4um | ProSci | 4 um | EUR 216.6 |
Uterus Tissue Slide (Adenocarcinoma) |
|||
| MBS154197-10um | MyBiosource | 10um | EUR 210 |
Uterus Tissue Slide (Adenocarcinoma) |
|||
| MBS154197-4um | MyBiosource | 4um | EUR 195 |
Uterus Tissue Slide (Adenocarcinoma) |
|||
| MBS154197-5x10um | MyBiosource | 5x10um | EUR 920 |
41253-2 RB UTERUS Y 25 EA* |
|||
| 41253-2 | Pel-Freez | 25 EA | EUR 263 |
Guinea Pig Uterus Genomic DNA |
|||
| GG-411 | Zyagen | 0.1mg | EUR 177 |
Guinea Pig Uterus Total Protein |
|||
| GT-411 | Zyagen | 0.5mg | EUR 153 |
Uterus cancer test tissue array |
|||
| T093 | TissueArray | each | EUR 78 |
|
Description: Uterus cancer test tissue array, with normal endometrial tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases/24 cores |
|||
Human Uterus Fetal Tissue Lysate |
|||
| IHUUTEFSTL100UG | Innovative research | each | EUR 1133 |
|
Description: Human Uterus Fetal Tissue Lysate |
|||
Human Uterus Tumor Tissue Lysate |
|||
| IHUUTETLT100UG | Innovative research | each | EUR 361 |
|
Description: Human Uterus Tumor Tissue Lysate |
|||
Leiomyoma of uterus tissue array |
|||
| SO806 | TissueArray | each | EUR 270 |
|
Description: Leiomyoma of uterus tissue array, 80 cases/80 cores |
|||
Monkey Rhesus Uterus Genomic DNA |
|||
| UG-411 | Zyagen | 0.1mg | EUR 210 |
Human Uterus Fetal Tissue Lysate |
|||
| MBS8420150-01mg | MyBiosource | 0.1mg | EUR 1465 |
Human Uterus Fetal Tissue Lysate |
|||
| MBS8420150-5x01mg | MyBiosource | 5x0.1mg | EUR 6415 |
Human Uterus Tumor Tissue Lysate |
|||
| MBS8420153-01mg | MyBiosource | 0.1mg | EUR 525 |
Human Uterus Tumor Tissue Lysate |
|||
| MBS8420153-5x01mg | MyBiosource | 5x0.1mg | EUR 2180 |
Guinea Pig Uterus Frozen Sections |
|||
| GF-411 | Zyagen | 10 slides | EUR 240 |
OORA00440-10U - GUINEA PIG UTERUS |
|||
| OORA00440-10U | Aviva Systems Biology | 1Each | EUR 80 |
OORA00440-1EA - GUINEA PIG UTERUS |
|||
| OORA00440-1EA | Aviva Systems Biology | 1Each | EUR 79 |
Guinea Pig Uterus Paraffin Sections |
|||
| GP-411 | Zyagen | 10 slides | EUR 228 |
Monkey Cynomolgus Uterus Genomic DNA |
|||
| KG-411 | Zyagen | 0.1mg | EUR 210 |
Human Uterus Lysate Membrane Fraction |
|||
| IHUUTETLM100UG | Innovative research | each | EUR 870 |
|
Description: Human Uterus Lysate Membrane Fraction |
|||
OCPB00088-100UG - Uterus Tumor Lysate |
|||
| OCPB00088-100UG | Aviva Systems Biology | 0.1mg | EUR 199 |
OCPB00611-100UG - Fetal Uterus Lysate |
|||
| OCPB00611-100UG | Aviva Systems Biology | 0.1mg | EUR 579 |
Human Uterus Lysate Membrane Fraction |
|||
| MBS8420152-01mg | MyBiosource | 0.1mg | EUR 1145 |
Human Uterus Lysate Membrane Fraction |
|||
| MBS8420152-5x01mg | MyBiosource | 5x0.1mg | EUR 4960 |
Total RNA - Human Tumor Tissue: Uterus |
|||
| R1235274-50 | Biochain | 50 ug | EUR 480 |
Rat Uterus, non-pregnant Total RNA |
|||
| RR-411 | Zyagen | 0.1mg | EUR 160 |
OCPB00744-100UG - Uterus Membrane Lysate |
|||
| OCPB00744-100UG | Aviva Systems Biology | 0.1mg | EUR 559 |
Uterus Tissue Slide (Spindle Cell Tumor) |
|||
| 11-418-10um | ProSci | 10 um | EUR 241.8 |
Uterus Tissue Slide (Spindle Cell Tumor) |
|||
| 11-418-4um | ProSci | 4 um | EUR 216.6 |